AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio
Mar 14, 2024 12:44 AM
(Reuters) - Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations,
you may see comments from our Community Managers.